• FuelPositive just filed its audited financial statements for the year ended September 30, 2021
• Initial demonstration systems for green ammonia production are scheduled for launch and validation, starting in mid-2022
• FuelPositive has also hired Counsel Public Affairs Inc. to offer government relations services
• It also announced the appointment of Jeanne Milne to lead the company’s efforts to secure government grants
• The company’s new head office will be located within the Kitchener-Waterloo area, and new staff will be joining the company once the space is secured

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) just filed its audited financial statements for the 2021 financial year, in what is projected to be the company’s best year yet, also announcing significant milestones, particularly with its demonstration project rollout scheduled for mid-2022 (https://ibn.fm/1HSU1). Financial materials are available publicly under the FuelPositive profile on the SEDAR website (www.sedar.com). The initial demonstration systems for the company’s green ammonia production system, which were scheduled for launch by mid-2022, are on schedule. Comprising of three elements- a nitrogen generator, a water electrolyzer, and a green ammonia synthesis reactor, FuelPositive is confident that it will begin validating the demonstration system in mid-2022. FuelPositive also announced the first demonstration pilot project- a 6,000-acre grain and plant-based farm located in Manitoba. This location will offer the company an avenue to test the production unit and show what it can do in the harsh Canadian climate. “We are on track to deploy our first prototype in Manitoba in late summer 2022,” noted Ian Clifford, the Chief Executive Officer (“CEO”) and Board Chair of FuelPositive. “Our first site visit, which was conducted last week, went extremely well and we are now finalizing our agreement with the farmer,” he added. FuelPositive has also brought on board Counsel Public Affairs Inc., one of Canada’s leading public affairs agencies, to offer government relations services going forward. Additionally, this agency will be working alongside Sussex Strategy Group to further the company’s interests. FuelPositive’s management notes that with its focus on decarbonizing agriculture and building energy independence, it shares various goals with all levels of government across Canada. As such, having Counsel Public Affairs Inc. as a partner would help it navigate through the market efficiently and achieve its set goals. “Counsel Public Affairs complements the team at Sussex Strategy Group, setting us up well to identify areas of common interest between FuelPositive and the provincial governments in Western Canada as they tackle climate change,” noted Mr. Clifford. In December 2021, FuelPositive appointed Dr. Claudia Wagner-Riddle, the first member of its Agriculture Sector Advisory Panel. The nomination aligned with the company’s goal to advise farmers on how to best use its green ammonia on their farms and reduce on-farm emissions. The company has announced that it is finalizing the membership of this panel, which would go hand in hand with the appointment of Jeanne Milne to lead the company’s efforts to secure government grants. Jeanne will lend her vast experience supporting small- and medium-sized enterprises to navigate shifting markets and helping tech companies to earn revenue from their innovations. She has also founded, managed, and grown two companies and has held various key leadership positions in an international consumer goods company. FuelPositive also announced its new head office location- the Kitchener-Waterloo area. A lease has been signed for office and lab space in the Catalyst 137 building in Kitchener, Ontario. The Company is continuing to look for manufacturing space in the same area of Ontario, which is convenient for international visitors, close to the major town of Toronto, and offers affordable housing for its employees. The company has also announced that it is actively recruiting new hires. Job descriptions have already been posted on the company’s website, and interviews are underway for critical positions, including but not limited to Mechanical Designer, Chemical Engineer, Tooling Technician, Junior Research Assistant, and Human Resources Consultant. FuelPositive’s management is excited about the company’s plans going forward and its technology’s potential, specifically with addressing global warming. “FuelPositive is moving forward at full speed to commercialize our in situ, modular, scalable and transportable green ammonia production system. As the weeks go by, the world is becoming increasingly excited about the potential of green ammonia to decarbonize our industries, offer control and energy independence to consumers, and provide food security for our future,” noted Nelson Leite, the Chief Operating Officer (“COO”) of FuelPositive. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Kaival Brands is the exclusive global distributor of products manufactured by Bidi Vapor LLC
• Bidi Vapor announced that it has been granted a judicial stay of the marketing denial order issued by the FCA in September 2021, which will permit the company to market all its products in the United States, pending the outcome of the lawsuit
• Kaival Brands expect the decision to result in a significant rebound in BIDI(R) Stick sales, with the company’s distribution partners expected to reestablish previous sales volumes

Kaival Brands Innovations Group (NASDAQ: KAVL), the exclusive global distributor of products manufactured by Bidi Vapor LLC (“Bidi Vapor”), including the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”), which is intended exclusively for adults 21 and over, announced, that the U.S. Court of Appeals for the Eleventh Circuit has granted a judicial stay of the marketing denial order (“MDO”) previously issued by the U.S. Food and Drug Administration (“FDA”) to Bidi Vapor in September 2021. The stay order, which was issued on February 1, 2022, allows Bidi Vapor and Kaival Brands to market and sell all of its BIDI(R) Stick ENDS, including its tobacco, menthol, and flavored products within the United States pending the outcome of the lawsuit; moreover, Bidi Vapor has also reiterated its intention to continue with its merits lawsuit which is set to compel the FDA to place Bidi Vapor’s Premarket Tobacco Product Application (‘PMTA’) for the favored ENDS back under scientific review. Bidi Vapor had previously submitted PMTAs for all 11 of their flavor varieties (9 flavored ENDS offerings in addition to Menthol and Tobacco) of its BIDI(R) Stick prior to the original September 9, 2020 PMTA deadline, with the detailed applications running to over 285,000 pages – including robust and reliable scientific data supporting that its flavored BIDI(R) Sticks provide an added benefit to adult smokers over tobacco-flavored ENDS. Nonetheless, the regulatory overview of the United States’ vape market remains largely a work in progress, with the FDA’s decision last September to take more time to process outstanding PMTA’s leading to a temporary removal of over 946 thousand flavored e-cigarette products from the US marketplace (https://ibn.fm/RnOl3). Kaival Brands have placed strict focus on their regulatory compliance from both, a manufacturing and retailing standpoint, with recent behavioral studies carried out by the company revealing that the majority of BIDI(R) Stick consumers were older smokers who were either able to transition completely away from smoking or were able to significantly reduce the number of daily cigarettes smoked. The company’s proactive and compliant stance has been reflected by the recent favorable judicial stay decision, which permits Bidi Vapor to resume marketing on all products in the United States, pending the outcome of the lawsuit. “We expect this judicial stay will result in a rebounding of BIDI(R) Stick sales,” said Niraj Patel, president and CEO of both Kaival Brands and Bidi Vapor. “Many wholesale and retail partners had discontinued or slowed purchases of the BIDI(R) Stick, until we heard back from the courts on the likelihood of our merits case succeeding,” Patel said. “This is what our wholesale and retail partners have been waiting for.” Patel further elaborated on the company’s compliances with FDA norms, as well as Bidi Vapor and Kaival Brands’ goal of providing adult smokers, 21 and older, with a viable alternative to combustible cigarettes. “We believe that Bidi Vapor has developed substantial, robust and reliable scientific evidence through, among other things, surveys, behavioral studies and clinical trials establishing support that the product is appropriate for the protection of the public health,” Patel said. “Following on FDA’s initial administrative stay of the MDO, we believe that this recent judicial stay is a good indication that the Court finds some merit in Bidi Vapor’s arguments and puts Bidi Vapor’s PMTA one step closer to being properly and fully evaluated by FDA”. For more information, visit the company’s website at www.KaivalBrands.com. NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

• GCAC announces another milestone that brings company closer to completing impending transaction with Cepton Technologies, a Silicon Valley developer of LiDAR-based innovative technology
• SEC declared effectiveness of Registration Statement and Special Meeting date for proposed business combination where stockholders will vote to approve transaction
• Cepton provides highly competitive price-for-performance LiDARs; initially targets advanced driver assistance systems (“ADAS”) segment but is poised to expand into new markets and applications

Growth Capital Acquisition (NASDAQ: GCAC), a special purpose acquisition company, announced that it would hold the Special Meeting of its stockholders at 10:00 A.M. Eastern Time on February 9, 2022, following the SEC’s declaration of the company’s registration statement on Form S-4 effective (https://ibn.fm/TKVG9). The proxy voting process is already in progress. Special Meeting will allow shareholders to consider the previously proposed business combination with Cepton, a Silicon Valley innovator of LiDAR-based technology. The meeting will be held online via live audio webcast at www.cstproxy.com/gcacorp/2022, entitling GCAC stockholders of record on January 13, 2022, to vote to approve the proposed transaction with Cepton. Relevant documents, including the definitive proxy statement, were mailed to GCAC’s shareholders of record as of the close of business on the Record Date on or about January 25, 2022. After closing the transaction, the combined company’s common shares are expected to list on Nasdaq under the ticker symbol “CPTN” while the warrants would list under “CPTNW.” The company announced that the merger with Cepton Technologies Inc. values Cepton at an enterprise value of around $1.5 billion on a cash-free, debt-free basis. As the race to fully autonomous vehicles (“AV”) and advanced driver assistance systems (“ADAS”) was accelerating, Cepton recognized that new technology — LiDAR, or light detection and ranging — could be the answer to some of the AV and ADAS challenges. Still, the LiDARs are yet to become commercialized for mass adoption as the technology’s application is mainly restricted to ultra-high-end vehicles. Founded in 2016 and led by industry experts to meet key LiDAR industry challenges for mass-market adoption, Cepton now serves a fast-growing customer base through an international presence across North America, Germany, Japan, India, and China. What differentiates Cepton from many of its competitors is its proprietary Micro Motion Technology (“MMT(R)”) which uses quartz-crystal-like materials instead of MEMS (micro-electro-mechanical systems). This feature allows Cepton to offer improved performance and lower power usage – all delivered at a better price point. Commitment to constant innovation in a space with a great potential for value creation, Cepton was awarded the CES(R) 2022 Innovation Awards Honoree in the Vehicle Intelligence & Transportation category with its Nova LiDAR — a miniature, wide field of view LiDAR sensor for near-range applications (https://ibn.fm/HGaHD). Focused on the mass market commercialization of its high performance, high-quality LiDARs, the company has also secured deals with Koito Manufacturing, General Motors (NYSE: GM), and Ford (NYSE: F). The deal with General Motors is the industry’s largest automotive OEM program, positioning Cepton as the first company to bring LiDAR sensors to production markets. As a result, the company is expected to slash production costs in half over the coming years – from around $1,000 to near $500 (https://ibn.fm/vsSGK). This watershed moment could potentially bring LiDARs from the industry’s fringes straight to the automotive mainstream. The anticipated start of production is set for 2023. For more information, visit the company’s website at www.GCACorp.com NOTE TO INVESTORS: The latest news and updates relating to GCAC are available in the company’s newsroom at https://ibn.fm/GCAC

• The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026
• Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three years
• Nemaura Medical has sought to capitalize on the blood glucose monitoring sector’s phenomenal growth rate through the launch of its proprietary body worn continuous glucose sensor in both the diabetes sector and consumer healthcare sector.
• The company’s flagship sugarBEAT(R) device provides diabetic and pre-diabetic patients with the ability to track their glucose levels without the use of needles or puncturing the skin – a concept previously thought to be highly implausible

The American Diabetes Association (“ADA”) recently published their recommendations for the Standards of Medical Care in Diabetes, advocating for all adults aged 18 years and older who were overweight, obese, or suffering from other diabetes and pre-diabetes risk factors to get screened. Moreover, the ADA also suggests that all adults be screened for diabetes beginning at age 35 years, with healthy patients repeating screenings at three-year intervals. As such, it comes as no surprise that a recent report delving into the blood glucose monitoring system market has forecast the sector to expand to an annual value of $27.2 billion by 2026, with a CAGR of 9.6% between 2021-2026 (https://ibn.fm/4V317). Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has sought to capitalize on the burgeoning growth within the sector through the release of its two flagship constant glucose monitoring (“CGM”) products, the sugarBEAT(R) and MiBoKo application. Over 420 million people globally are currently living with diabetes, with pre-diabetic cases totalling almost three times that number. Meanwhile, and in the US alone, over $760 billion was spent on diabetes-related health care expenditures during 2019, equating to an average annual spend upwards of $9,000 per diabetic patient compared to approximately $1,600 for a healthy individual (https://ibn.fm/1zyrx). A rise in the global diabetic population has led to an exponential increase in the use of constant glucose monitoring devices, a critical technological innovation providing both diabetic and pre-diabetic individuals with early detection of hypo and hyperglycaemic conditions. Nemaura Medical has long made it its corporate mission to develop non-invasive wearable diagnostic devices designed to help diabetic and near-diabetic patients monitor blood glucose levels by measuring blood makers at the surface of the skin. Its revolutionary sugarBEAT(R) CGM device provides users with non-invasive glucose monitoring; as described by the company, it works by “drawing a small number of selected molecules, such as glucose into a patch placed on the skin. These molecules are drawn out of the interstitial fluid which naturally sits just below the top layer of skin.” (https://ibn.fm/O2GXl). The company has followed up on the successful pre-launch campaign of its sugarBEAT(R) technology in the UK by its UK licensee, which has already garnered orders for 200,000 sensors in the United Kingdom, with the release of the MiBoKo application. The MiBoKo application, a service offering that has been in development over the past 18 months, and uses a non-invasive glucose sensor to determine users’ Metabolic Score, which is based on glucose tolerance or insulin resistance. The device is linked to an AI mobile application, which seeks to provide users with personalized information by tracking their metabolism. Users will be able to find out how well their body responds to sugar through their metabolic health score — and how what they eat and what they do every day uniquely affects their metabolic health. With constant glucose monitoring devices rapidly gaining proponents amongst endocrinologists and the public alike, Nemaura Medical has set out to produce what was hitherto thought to be implausible – a revolutionary product through which patients can monitor their sugar levels which do not require any needles or necessitate the individual to puncture their skin at all. For more information, visit the company’s website at www.NemauraMedical.com. For more information on MiBoKo, visit www.Miboko.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Kronos’ planned West Virginia factory improvements are on schedule, expected to finish in Q1 2022
• The company is currently developing new consumer electronics products in the wellness category
• Kronos has filed an S-1 with the SEC regarding a proposed secondary stock offering
• The company is preparing to manufacture its patented air purifiers in its U.S. factory to satisfy increasing demand
• Kronos will increase production of its 5-ply graphene mask, the only one of its kind made in the United States

Kronos Advanced Technologies (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings. Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of a traditional HEPA filter. Kronos(R) not only collects but destroys air pollutants. Kronos(R) AIR 5G(R) Air Purifiers use about 30,000 volts inside to actively destroy 99.99% of all airborne bacteria, mold, and virus particles. Kronos(R) devices operate silently using nanotechnology to remove 100% of pollutants in a 400ft2 room (up to the whole house) and replenishes the room with pure, clean air every 15 minutes. Indoor household air is often four times more polluted than outdoor air, and Kronos air purifiers act like bionic lungs for the home and protect the people in it. Unlike traditional HEPA systems that collect pollutants on filters which can, over time, grow mold and bacteria, Kronos’ patented technology destroys and eliminates all manner of harmful particles and deposits them on easy-to-clean collecting plates. This reduces the risk of harmful particles in the air and eliminates the need to replace costly HEPA filters every month. The Kronos(R) AIR 5G(R) Air Purifier destroys and eliminates dust, allergens, bacteria, and even viruses. The AIR 5G(R) has been third party lab tested and confirmed to kill 99.87% of influenza virus in one hour. The patented system’s five step process starts with a pre-filter screen that filters and collects hair, pet dander, etc. The air is then pulled through emitter wires which create a 30,000-volt electro field that zaps dangerous particulates. In the ionic field, charged particles are destroyed, killing bacteria and pathogens. The particles are then captured on collecting plates, removing dangerous toxins from circulation. The collecting plate is easily cleaned and reused without buying new filters. The catalytic layer is the final step in the purification process, removing odors and keeping the air fresh and pure. The AIR 5G(R) has Smart Control Auto Mode, which measures and displays the air quality in the room and self-adjusts fan speed based on how dirty the air is in the room. There’s also an AIR 5G(R) Smart App that displays the real time Air Quality Index and acts as a remote control. The Kronos(R) AIR 5G(R) Air Purifier is offered in three models:

• Kronos(R) AIR 5G(R) X3 air purifier combines powerful patented TPA(R) technology with a compact form factor up to six times smaller than other air purifiers, with washable and reusable filters.
• Kronos(R) AIR 5G(R) X5 thoroughly wipes out dust, smoke, dander, bacteria, pollen, viruses, odors, germs, and more from the air, delivering the healthiest breathable air possible. It was developed for some of the world’s most polluted areas and is now available for use in the home. It runs completely silently, passing through five stages of purification to guarantee the cleanest possible air in homes or offices.
• Kronos(R) AIR 5G(R) X8 delivers maximum power, more than doubling the capacity and efficiency of the Kronos X5, with CADR speeds of up to 470 CFM – enough to clean a 1,000ft2 room in just 20 minutes.

Kronos also offers the Kronos Car Air Purifier, the most advanced car air purifier with Kronos’ patented TPA(R) technology, and FitAir, the best personal air purifying solution that brings clean air anywhere by cleaning within 25ft2 of personal space at an airflow rate of 3x per hour. Market Overview The global air purifier market was valued at $10.38 billion in 2020 and is expected to reach $21.15 billion by 2027, achieving a CAGR of 10.7% over the forecast period, according to Brandessence Market Research. The market is primarily driven by the increasing concerns about both outdoor and indoor air pollution, coupled with the associated health problems. Air pollution is one of the most prevalent concerns, due to worsening environmental condition. According to Health Effect Institute, it accounts for 4.9 million to 8.8 million deaths worldwide each year. Furthermore, as most of our time is spent is indoors, indoor air pollution remains a serious concern to individuals, as well as regulatory agencies. Particles like PM 2.5 can enter indoors through a wide range of sources including car engines, fireplaces, and coal- or natural gas and the infiltration of ambient particulates in urban areas. Even in the absence of solid fuels, indoor ventilation can build up PM 2.5 particles to a greater extent than in outdoor environments. Growing demand for portable air purification filters and systems in urban areas, increased advancements to catch key particulates like coronavirus, and increased regulatory measures to ensure safe environments for professionals in the industrial sector remain leading drivers of growth in the air purifier market. Poor indoor air quality can cause fatigue, headache, and irritation of the eyes, throat, lungs, and nose, which can have a negative impact on worker productivity. Some air contaminants can cause asthma and other respiratory diseases. Air purifier adoption is increasing rapidly in the U.S. to minimize health issues caused by poor air quality. Strict air quality standards, guidelines, and regulations in the U.S. are expected to have a positive impact on the market. For instance, the New Jersey Indoor Air Quality standard, NJAC 12:100-13 (2007), sets guidelines and standards related to indoor air quality during working hours in public employee-occupied buildings. Key manufacturers are focusing on acquisitions and mergers to expand their geographical reach and strengthen their position in the market. Management Team Michael Rubinov, President and Head of Business Development A seasoned hi-tech executive with 25 years of global business experience, Mr. Rubinov has served in various positions in sales, marketing, channel development and partner management. He has worked for large and global organizations such as Intel, NICE Systems, and Boeing (Defense and Security), as well as for start-up companies like Dialogic and Remunera International SA. He was appointed President and Head of Business Development of Kronos Advanced Technologies Inc. in February 2020. Mr. Rubinov holds an MBA, an MS Computer Sciences, and a BS Electrical Engineering. Joseph L. Florence, Chief Operational Officer & CTO A dynamic skilled leader in all aspects of business formation, evaluation, and execution, Mr. Florence brings a unique combination of Fortune 100 company experience with a lifetime of entrepreneurial experience to the Kronos team. He is a gifted visionary, possessing the unique ability to see future opportunities and make timely strategic adjustments and is naturally gifted at seeing unrecognized risk and overlooked opportunities. Mr. Florence has a proven track record of transforming companies to better align people, processes, and technologies to meet strategic goals and business metrics resulting in increased market share and profitability. For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

• Cepton Technology is coming public this month via a merger with SPAC Growth Capital Acquisition Corp.
• Cepton is a leader in lidar technology, working with all the top automotive OEMs and signing the largest lidar contract to date where its MMT will be used in General Motors’ Ultra Cruise ADAS
• Cepton recently hosted a Virtual Investor Day where the management team provided comprehensive insight into the past and future as it targets $1.22 billion in revenue is 2026

Occasionally, an industry emerges that fundamentally changes the game. In the automobile industry, the future is autonomous driving, starting with Advanced Driver Assistance Systems (“ADAS”) before it evolves into full-on driverless technology. According to Dr. Jun Pei, CEO of Cepton Technology, the future of autonomous will include a combination of lidar (light detection and ranging), camera, and microwave technologies working seamlessly to keep passengers safe in vehicles. In the words of Dr. Pei during a recent Virtual Investor Day, don’t think Cepton is “just another lidar story;” Cepton is writing lidar’s history, including winning the largest ADAS lidar contract to date.

Cepton is coming public through a merger with special purpose acquisition company Growth Capital Acquisition (NASDAQ: GCAC), with a shareholder vote on the merger scheduled for February 9. Ahead of the meeting, GCAC has accumulated approximately $172.5 million in trust, plus another $59.5 million via a PIPE (private investment in public entity).

During the two-hour presentation, Cepton’s leadership team took turns detailing the company and the industry in a highly informative and easy-to-understand manner that illustrated exactly why Cepton is differentiated from any peers in the lidar space. From the minutiae to the broad strategy, Pei and company made it easy to see why Cepton was selected by GCAC founders after exploring over 100 potential acquisition targets for the SPAC.

Lidar and associated technology can be complex and intimidating for those outside engineering circles, which Pei, who received his Ph.D. in Electrical Engineering from Stanford University, seems to have a firm grip on when providing insight on Cepton technology. He lays out exactly how the company got to where it is today since formation six years ago with the specific purpose of becoming the dominant force in mass market lidar.

Lidar uses infrared beams of light, shooting them into space, recording the travel time to reflect home, and then using equations to determine distance. When combined with computing power, lidar creates a map of the environment that undergirds autonomous driving and vehicle safety. Heralded for the last decade as the future for cars, lidar engineers faced countless obstacles for what Pei calls the three pillars of lidar: performance, cost, and reliability.

To overcome these challenges, Cepton looked to some time-tested and auto-approved technologies for illumination and detection and married it with their own patented tech called MMT(R) (micro-motion technology). In summary, MMT(R), is a microscopic optical array merged with a voice coil being microscopically driven over a magnet. It is completely frictionless with no complex optical components and stunning performance.

These qualities resulted in a partnership with Koito, the biggest Tier 1 automotive lighting company in the world, and General Motors (NYSE: GM), which is now solely using Cepton’s lidar technology in its vehicles through 2027. More precisely, Cepton’s lidar is the center point of GM’s new Ultra Cruise ADAS, its upgraded version of its popular Super Cruise tech that will make hands-free driving possible on essentially every road in the U.S., an industry first. The contract is, hands down, the biggest the lidar industry has ever seen. It is not merely a contract to put Cepton’s lidar on one model of a GM vehicle. It will be used for every vehicle in the GM family receiving Ultra Cruise.

Throughout the Investor Day presentation, the company provides a bevy of insight on how onerous a path it is for an upstart (or any company for that matter) to win such a contract from a Tier 1 automaker, including the design process, the importance of Koito as a partner, and all the software and hardware work necessary to build what is arguably the most advanced lidar system available today, complete with Cepton’s own low-power, sesame-sized ASIC chip that handles all the processing.

Part of the genius of Cepton’s LiDAR is its versatility. With its tiny footprint, it can go behind windshield, in Koito headlamps, or on the vehicle body, whatever the OEM wants. And, according to Brunno Moretti, VP of Product Marketing, lidar seeing booming demand. “Every OEM that I’ve talked to…sees lidar as a necessity, sees it as a way to get to fewer accidents,” said Moretti during the investor presentation.

Management went on to enlighten shareholders about how it continues to build a rigid barrier to entry to ward off any potential competition as part of its go-forward strategy. For starters, working intimately with companies like GM, Ford (NYSE: F), Koito and other top names provides validation and a rapport that is not easily duplicated as one becomes integral to their infrastructure. Cepton has had “boots on the ground” in Detroit for years making sure it is meeting any demands automakers require.

Owing to confidentiality agreements, Cepton cannot disclose all the companies it is working with, but it did share that it has engagements with nearly 200 companies across many verticals. Cepton is working on optimization of MMT(R), as well as new technologies, including sharing a video clip demonstrating its SLAM (simultaneous localization and mapping) tech.

According to Mitch Hourtienne, VP of Business Development at Cepton, the new product launch of Ultra Cruise has tremendous potential to scale after the initial roll-off in 2023. Opportunities should abound in new models and geographic expansion, plus potentially new alliance partners akin to the way Honda is adopting GM’s Super Cruise on certain models.

The presentation also included a financial section that gave CFO Winston Fu an opportunity to discuss the revenue forecast through 2026, when revenue is expected to reach $1.22 billion. While GM certainly is a key influencer, the overall revenue plan is diversified throughout hundreds of engagements with other companies highly interested in incorporating lidar technologies. Fu went on to detail the strategy on customer retention and lowering selling price points while simultaneously expanding gross margins, which should exceed 50% in 2025.

Cepton’s team spent nearly an hour fielding and answering questions from shareholders that provided additional perspective on decisions and where the company is headed, including very specific topics (scalability, hurdles, illumination design, etc.).

What is evolving for Cepton is a beachhead market where Cepton has the opportunity to gain a dominant market share in the auto industry while positioning to address adjacent markets where lidar is applicable. Confident in the company’s position, Pei quipped, “You don’t have to project who the winner is. Cepton is already the winner.”

For more information, visit the company’s website at www.GCACorp.com

NOTE TO INVESTORS: The latest news and updates relating to GCAC are available in the company’s newsroom at https://ibn.fm/GCAC

• In 2021, Lexaria conducted several main studies evaluating DehydraTECH-processed CBD and nicotine
• The company has big plans for 2022, a year it expects to undertake three ground-breaking studies
• Lexaria hopes these three major studies will generate sufficient data to support either regulated IND-type applications or to stimulate corporate partnerships
• The company is eying larger national and international applications for DehydraTECH with the aim of generating revenue through licensing fees and royalties

For Lexaria Bioscience (NASDAQ: LEXX), a drug delivery company whose patented DehydraTECH(TM) technology has proven effective in improving bioavailability, speed of onset, and efficiency of orally-delivered fat-soluble active molecules and pharmaceuticals, 2021 was a year of myriad milestones. In an annual letter to shareholders, company CEO Chris Bunka underlined that January 2021 marked the birth of a modern version of the company (https://ibn.fm/Djp5l). “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018! We have conducted studies across broad areas of interest, but also concentrated in specific areas where we have had supportive data,” writes Bunka. Last year, Lexaria’s most significant area of investigation was DehydraTECH-processed cannabidiol (“CBD”) for the potential treatment of hypertension and heart disease. The company conducted HYPER-H21-1, its first human study of 2021, that showed that human blood pressure (“BP”) decreased within minutes of ingesting a single dose of DehydraTECH-CBD capsules. Its follow-up study, HYPER-H21-2, in which participants received three doses of DehydraTECH-CBD and were monitored over a 24-hour ambulatory period, showed a 23% average decrease in BP, relative to placebo, among patients with mild to moderate hypertension. Over the 24 hours, the reduction in BP averaged 7.0%. The study also evidenced reduced arterial stiffness among the volunteers. Encouraged by the findings and building on the same, Lexaria has big plans for 2022. Starting in April or possibly sooner, the company plans to begin dosing in its largest-ever hypertension study. “If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” Bunka adds. Bunka also expressed the company’s plans to expand its DehydraTECH-CBD program by exploring other development opportunities. Specifically, before this Spring, Lexaria expects to launch a complex animal study to evaluate DehydraTECH-CBD as a potential treatment to inhibit seizure activity in animals. The company has also announced its intention to pursue efficacy modeling through 2022 with its DehydraTECH-CBD in animals for other possible therapeutic indications, namely dementia, rheumatoid diseases, and diabetes. In addition, 2021 saw the company undertake a nicotine animal study wherein it evidenced that DehydraTECH effectively promoted nicotine delivery characteristics in sublingual/buccal (oral tissue). The study offered yet another opportunity for the company to demonstrate DehydraTECH’s versatility to work effectively in different parts of the body, opening doors to drug delivery through multiple other products. Based on these successes, Lexaria plans to launch a similar study in humans, expected to “start soon.” Bunka believes that if the company demonstrates a similar performance of nicotine absorption in humans, it will have achieved another significant milestone as it journeys toward the commercial applicability of its technology. Further, Bunka voices his enthusiasm at 2022, noting: “The goal of our three major studies is to generate sufficient data to support either regulated IND-type applications or to stimulate corporate partnering within their appropriate market sectors. We are optimistic of positive results – noting that science can be unpredictable – and, if so, expect 2022 to be our most exciting year ever!” In addition, Lexaria strengthened its IP portfolio with the receipt of five new patents in 2021, which brought its total to 23 granted globally. As well, it up-listed to the Nasdaq Capital Markets, where it raised $11 million in gross proceeds budgeted to finance its R&D initiatives and operations. Bunka also lays stress on the company’s longer-term goals as regards revenue generation. Whereas Lexaria generated its highest-ever revenues in 2021 of over $720,000, mainly due to its DehydraTECH licensing arrangements with its existing clients, the company is primarily focusing on larger national and international applications for DehydraTECH, chiefly but not limited to the pharmaceutical sector. Accordingly, Lexaria is targeting licensing fees, milestone payments as well as royalties. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022
• The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University
• Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans
• Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation clinical trial in the second quarter (“Q2”) of the 2022 financial year, with primary endpoints of three and six months. The study will build previous research conducted by Dr. Matthew Johnson, Ph.D., and his team at Johns Hopkins University. Their ongoing study is showing 59% of participants who received psychedelic-assisted therapy remained abstinent from smoking at 12 months. In comparison, only 28% of patients who received the transdermal nicotine patch remained abstinent (https://ibn.fm/KvEUG). In readiness for the trial, Mydecine has submitted a pre-Investigational New Drug (“IND”) briefing package to the United States Food and Drug Administration (“FDA”). The submission will allow the company to evaluate its lead drug candidate, MYCO-001, in a structured smoking cessation treatment program, aiming to introduce the product in the market as early as 2024. “We are excited to move forward on this important study, and our team has been working diligently to ensure that our pre-IND package is complete,” noted Josh Bartch, the Chief executive Officer (“CEO”) of Mydecine. “As the only company currently investigating a psilocybin compound for smoking cessation, Mydecine is proud to be at the forefront of this research,” he added. Dr. Johnson, a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University (“JHU”), will be the Principal Investigator in this clinical study. The planned placebo-controlled study will be conducted at JHU, and the research will feature a combined phase that will utilize results acquired throughout the trial to adjust the course of the study. According to the Centers for Disease Control and Prevention (“CDC”), in the United States alone, cigarette smoking is responsible for one out of every five deaths, representing an estimated 480,000 deaths every year. With about 34.1 million Americans smoking cigarettes, there is a growing need for smoking cessation alternatives, an opportunity that Mydecine is looking to tap into. “Tobacco use is the greatest single, preventable cause of death in the world, yet there are few safe and effective treatments for nicotine addiction,” noted Mr. Bartch. “With safety and efficacy concerns about current therapies, including the recall of the blockbuster treatment Chantix, there is a strong need for innovative and improved treatment options,” acknowledged Dr. Rakesh Jetly, the Chief Medical Officer (“CMO”) at Mydecine. The pre-IND briefing package submission edges Mydecine closer to launching its MYCO-001 to the market. It is a tremendous milestone for the company and shows great promise for smoking cessation treatments. In addition to smoking cessation, Mydecine is also exploring the use of psilocybin in treating Post-Traumatic Stress Disorder (“PTSD”). In what marks another significant move for the company, it just entered into a partnership with Combat Stress to use psilocybin in a psychedelic-assisted psychotherapy PTSD treatment program for veterans (https://ibn.fm/Gp3u9). The company further confirmed that Combat Stress, one of the leading charities in the United Kingdom working with veterans, will be one of the several sites for its upcoming clinical trials, set to launch later in the year. The study will be led by Professor Dominic Murphy, the Head of Research at Combat Stress and the UK Psychological Trauma Society’s president. “I am truly excited to be leading this study at Combat Stress,” noted Professor Murphy. “This collaboration offers great potential for research focused on new, innovative therapeutics that offer significant opportunities to bring hope to those veterans still living with the trauma of their military experiences,” he added. Data collected from this study will be integral to Mydecine advancing its drug development pipeline, coupled with its ability to bring a much-needed novel treatment to market. The company is also confident that there are more opportunities to expand its clinical trials and deliver on its mission to come up with safe and effective alternative medicine that people can trust with this partnership. “There is a big unmet need when it comes to treating PTSD and other mental health conditions, especially within the veteran population, and this partnership demonstrates the strong progress we continue to make in bringing psychedelic-assisted psychotherapies to the forefront of the market and bring hope for all those struggling with these conditions,” reckoned Mr. Bartch. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Tingo has made it its corporate mission to transform the way rural business in Africa is conducted, thereby helping millions of people across Africa improve their economic prospects
• The company has based their business model around several key tenets, namely – the provision of technology through its unique ‘device-as-a-service’ model, access to financial services through TingoPay and access to market through Nwassa digital Agri-Marketplace
• Alongside its corporate aspirations, Tingo has also adopted a number of the United Nations Sustainable Development Goals (“SDG’s”), through which it seeks to invest in the future of its millions of stakeholders

For the past 50 years, Daisy Namusoke has grown crops on her small plot of land in the Buikwe District of Central Uganda, mostly to feed her husband, five children, and two grandchildren (https://ibn.fm/RdC8O). Like most smallholder farmers in Africa, she cultivates a mix of crops, relies on saved seeds and those purchased from local sources, and uses little by way of external inputs, such as synthetic fertilizers. When selling her crops, she is forced to sell to middlemen – a practice which subjects’ farmers to thin margins and habitually short-changes them on the fruit of their labor. Tingo (OTC: TMNA), a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa, has made it its mission to change the way rural business in Africa is conducted, in the process helping millions of people across the continent improve their quality of life, income and prospects. The agricultural sector is the largest economic sub-set within Nigeria’s economy, representing 24 percent of the country’s Gross Domestic Product (“GDP”) as of 2020 and playing a pivotal role in the growth of the country. The crucial role of the sector has driven Tingo towards addressing some of the principal challenges that farmers and other stakeholders within the Nigerian agricultural value chain are current facing. Tingo’s business model is underpinned by four key pillars, namely – Device-as-a-Service, whereby farmers are provided access to smartphones and mobile internet; Tingo Mobile Network; which seeks to provide mobile connectivity and reception in remote and rural locations; TingoPay, a unique Africa-centric payments service; and Nwassa, their digital agricultural marketplace. Through the combination of the four pillars, Tingo has sought to bundle a complete, digitally inclusive ecosystem which promotes financial inclusion, delivers disruptive micro-finance solutions, produces social upliftment in rural communities and unveils domestic and international opportunities to Africa’s rural farmers. Tingo’s Nwassa platform has rapidly become a key tool for the close to 10 million agri customers and stakeholders that the company supports. Third quarter results revealed that the platform has generated $120.7 million as income as of the first nine months of 2021. By year-end, the Nwassa platform is forecast to have processed up to $4 billion in transactions, the process generating upwards of $160 million earnings, which in turn will account for approximately 38 percent of Tingo Inc’s revenues, up from only 17 percent in 2020. Tingo’s business model has, rather uniquely, sought to deliver attractive returns to shareholders whilst simultaneously, investing in the long-term future of the company and its millions of stakeholders. To do so and in addition to its commercial focus, the company has adopted five core sustainable development goals as its corporate mission, namely – ensuring food security, driving poverty alleviation, promoting digital financial inclusion, encouraging job creation, and supporting female entrepreneurship and empowerment. Over the past 20 years, Tingo has sought to commit towards developing solutions which support the long-term aspirations of rural farming communities across the African continent. Driven by an unrelenting mission to uplift rural communities and support growth in developing economics, Tingo Inc has shown that it is indeed possible to achieve the most sought-after maxim in impact investing today – making returns whilst doing good. For more information, visit the company’s website at www.TingoGroup.com. NOTE TO INVESTORS: The latest news and updates relating to TMNA are available in the company’s newsroom at https://ibn.fm/TMNA

Businesses, HR managers, and corporate leaders are invited to attend the Future Workforce Conference on February 16-18, 2022, as a virtual online event. The conference sessions are specially curated for industry decision-makers who have responsibilities in Human Resources, Employee Experience & Engagement, Learning and Development, Talent Acquisition, Workforce Strategy & Development, Change Management, Performance Management, Strategic Planning, People Data & Analytics Strategy, and so on. At the Future Workforce Conference, vendors can directly connect with the target businesses investing in digital, remote, and hybrid workforce in their organizations. Top reasons to attend:

• Learn to build a robust workforce strategy
• Incorporate new skills and collaborations through human-machine collaboration
• Driving digital innovations and transformation within the organization
• Understand and utilize people analytics for talent acquisition and retention
• Learn and get inspired from peers and understand what is driving other workforces
• Witness the enigmatic gathering of experts and corporate decision-makers

The event will discuss eminent speakers discussing the best practices for virtual onboarding remote workers in an organization. The conference will commence with opening keynotes about the human approach to workplace culture. The agenda on day 2 of the event includes discussions on talent acquisition, operations and analytics in the future of work. HR leaders will speak about the HR digital strategies and the evolving role of an HR professional. Further, the strategies for hiring employees in the post-pandemic era as well as digital transformation and the future of work will be some important topics at the conference. Industry decision-makers will share insights on digital listening strategies which is the key for an elevated employee experience. The Future Workforce Conference will showcase a panel of speakers discussing the future of HR technology, workforce development and employee experience. The speaking faculty includes HR heads, business partners, and workforce strategists of global organizations who possess years of experience in their work area. Attendees can leverage this phenomenal platform to connect with industry leaders. They can discuss their queries as well as learn tips and technologies of the evolving workforce strategies in the emerging digital landscape. To learn more, please visit https://ibn.fm/Gi21v.